Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday. Other ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Wegovy’s list price in the U.S. is over $1,300 for a month’s supply. It is five times the price in Canada ($265) and 14 times ...

Wegovy's list price in the U.S. is over $1,300 for a ... The right-wing argues, as the Heritage Foundation's Project 2025 ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...